Here are the 10-K annual reports from Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A (BRKRP) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BRKRP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BRKRP filings page.
Bruker Corporation files its annual report describing a global business built around four segments: BSI BioSpin, BSI CALID, BSI NANO, and BEST, focused on advanced scientific instruments and superconducting materials. The company serves life science, biopharma, materials, semiconductor, microbiology, diagnostics, and government markets with NMR, mass spectrometry, X-ray, microscopy, spatial biology, diagnostics, and superconducting technologies.
Bruker reports an aggregate market value of non‑affiliate stock of $4,251,097,535 as of June 30, 2025, with 152,219,250 common shares and 2,760,000 Series A mandatory convertible preferred shares outstanding as of February 20, 2026. Backlog was about $2,569.4 million at December 31, 2025, and the workforce totaled approximately 11,085 employees worldwide. Key risks highlighted include supply chain constraints, tariffs, reduced U.S. and Chinese research funding, geopolitical tensions, currency fluctuations, competition, and potential impairment of goodwill and other long‑lived assets.